Biogen’s Alzheimer’s drug wins FDA approval

After months of anticipation, Biogen Inc. (Nasdaq: BIIB) has won a coveted — but controversial — approval from the U.S. Food and Drug Administration for aducanumab, its blockbuster drug to treat early-onset Alzheimer’s disease. Read More

Read More